Figures & data
Table 1 Baseline characteristics of study population
Figure 1 (A) Non-CKD patients (n = 641): ROC curve analysis for NT-proBNP identifying CHF. (B) CKD patients (n = 358): ROC curve analysis for NT-proBNP identifying CHF. (C) non-CKD patients (n = 641): ROC curve analysis for NT-proBNP predicting death. (D) CKD patients (n = 358): ROC curve analysis for NT-proBNP predicting death. (E) CKD patients (n = 358): comparison of ROC curve predicting death between NT-proBNP and the three-variable model. (F) CKD patients (n = 358): comparison of ROC curve predicting death between NT-proBNP and the six-variable model.
![Figure 1 (A) Non-CKD patients (n = 641): ROC curve analysis for NT-proBNP identifying CHF. (B) CKD patients (n = 358): ROC curve analysis for NT-proBNP identifying CHF. (C) non-CKD patients (n = 641): ROC curve analysis for NT-proBNP predicting death. (D) CKD patients (n = 358): ROC curve analysis for NT-proBNP predicting death. (E) CKD patients (n = 358): comparison of ROC curve predicting death between NT-proBNP and the three-variable model. (F) CKD patients (n = 358): comparison of ROC curve predicting death between NT-proBNP and the six-variable model.](/cms/asset/8f96c945-c55f-4b8c-adf8-b7b30a51ab35/dcia_a_42700_f0001_c.jpg)
Table 2 Hazard ratios of NT-proBNP in elderly Chinese coronary artery disease patients with and without CKD
Figure 2 (A) Non-CKD patients (n = 641): Kaplan–Meier estimate of survival according to the cutoff point of NT-proBNP (369.5 pg/mL). (B) CKD patients (n = 358): Kaplan–Meier estimate of survival according to the cutoff point of NT-proBNP (2584.1 pg/mL).
![Figure 2 (A) Non-CKD patients (n = 641): Kaplan–Meier estimate of survival according to the cutoff point of NT-proBNP (369.5 pg/mL). (B) CKD patients (n = 358): Kaplan–Meier estimate of survival according to the cutoff point of NT-proBNP (2584.1 pg/mL).](/cms/asset/c9197d01-4221-4ef4-aa2f-2115adfc0b61/dcia_a_42700_f0002_c.jpg)
Table 3 Prognostic value of NT-proBNP and other models in elderly Chinese patients with both coronary artery disease and chronic kidney disease